Paper Details

  1. Home
  2. Paper Details

Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator.

Author: BonnaudG, HaahtelaT, LunaJ M, LutskyB N, O'ConnorB, QuerfurtH, WegenerT

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Mometasone furoate dry powder inhaler (MF-DPI) at a total daily dose of 400 microg provides clinical benefit comparable to fluticasone propionate Diskhaler 250 microg twice daily in patients with moderate persistent asthma.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Mometasone furoate (MF; Schering-Plough, Madison, NJ), is a glucocorticoid with high local potency and low potential systemic availability. OBJECTIVES: To compare the relative efficacy and safety of a new formulation of MF, coupled with a recently designed dry powder inhaler (DPI), in t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S1081-1206(10)62485-4

データ提供：米国国立医学図書館（NLM）

Mometasone Furoate Dry Powder Inhaler: A Breath of Fresh Air for Asthma

Asthma, a common respiratory condition, can make everyday life feel like traversing a desert of breathlessness. This clinical trial investigates the effectiveness and safety of [mometasone furoate (MF) dry powder inhaler (DPI)] in treating [moderate persistent asthma]. The researchers compared the efficacy of different doses of [MF-DPI] to [fluticasone propionate (FP) Diskhaler], a standard treatment option, and found that [MF-DPI] provided comparable clinical benefits to [FP Diskhaler] at certain doses. The study suggests that [MF-DPI] could be a valuable alternative for managing [moderate persistent asthma].

Finding Oasis in the Desert of Asthma: A New Treatment Option?

The study's findings suggest that [MF-DPI] could be a viable and effective treatment option for [moderate persistent asthma]. The fact that [MF-DPI] provided comparable clinical benefits to [FP Diskhaler], a well-established treatment, opens up new possibilities for managing this condition. The study's results are like a refreshing spring in the desert of asthma research, offering hope for new and effective treatments.

Living in the Oasis: Managing Asthma Effectively

The desert of [asthma] can be a challenging landscape to navigate. This study highlights the importance of having a variety of effective treatment options available. Consulting a healthcare professional to determine the best treatment approach for your specific needs is essential. Remember, even in the midst of the desert, there are ways to find relief and manage your condition.

Dr.Camel's Conclusion

The desert of [asthma] can be a difficult place to breathe, but this study shows the potential of [MF-DPI] to offer a refreshing oasis for patients seeking relief. The study's findings provide a valuable contribution to the search for effective treatments for [moderate persistent asthma]. Remember, with the right tools and support, we can navigate even the harshest of deserts.

Date :
  1. Date Completed 2001-05-21
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

11345282

DOI: Digital Object Identifier

10.1016/S1081-1206(10)62485-4

Related Literature

Article Analysis
・Effects of mometasone oral inhalation
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.